1. Growing need for primary care physicians caring for cancer survivors;Xierali;J Am Board Fam Med,2022
2. Minimal residual disease (MRD) detection in solid tumors using circulating tumor DNA: a systematic review;Zhu;Front Genet,2023
3. Searching for the “Holy Grail” of breast cancer recurrence: a narrative review of the hunt for a better biomarker and the promise of circulating tumor DNA (ctDNA);Gao;Breast Cancer Res Treat,2024
4. Centers for Medicare & Medicaid Services (CMS). Billing and coding: MolDX: minimal residual disease testing for solid tumor cancers. Available at: https://www.cms.gov/medicare-coverage-database/view/article.aspx?articleId=58456. Accessed July 16, 2024.
5. National Comprehensive Cancer Network (NCCN). Biomarker Compendium. Available at: https://www.nccn.org/compendia-templates/compendia/biomarkers-compendium. Accessed May 29, 2024.